Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 353 followers
Latest posts
Last updated 20 days ago
Invitation to Roche’s Half Year Results 2025 Presentation
20 days ago
Roche will publish its Half Year Results of 2025 prior to the...
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
23 days ago
Positive phase I/II data presented at the 2025 International Society on Thrombosis...
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
25 days ago
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival...
Reminder: Invitation to Roche’s Virtual Hematology Investor Event
28 days ago
We are pleased to invite investors and analysts to participate in our...
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
30 days ago
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
about 1 month ago
After a thorough clinical review, the benefit-risk for the use of Elevidys...
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
about 1 month ago
46% reduction in the risk of disease progression or death, and 27%...
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
about 2 months ago
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
about 2 months ago
Patients on fenebrutinib had low relapse rates with data showing no active...
Invitation to Roche’s Virtual Hematology Investor Event
about 2 months ago
We are pleased to invite investors and analysts to participate in our...
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
about 2 months ago
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in...
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
about 2 months ago
The strategic collaboration with Broad Clinical Labs will explore and develop applications...